ESR1 and breast cancer: Thus, Costa and coworkers explored a group of ER+ breast cancer patients undergoing treatment with the combination of CK4/6 inhibitors with the anti-estrogen letrozole and observed that, in patients developing resistance to this treatment, some tumors acquired RB1 loss, whereas other tumors lost PTEN expression [184].